EGFR-Mutant NSCLC: Second-Line Treatment Options and Safety Data

Shared insight into the complexities in treating EGFR mutant lung cancer during the second-line therapy phase, including safety profiles of different treatment regimens, managing toxicities, and ongoing research to improve patient outcomes.